Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease
Abstract
Introduction:
Diabetes mellitus (DM) and chronic kidney disease
(CKD) accelerate the process of atherosclerosis. To improve clinical outcomes,
non-invasive imaging modalities have been proposed to measure and monitor
atherosclerosis. Recently, colour M-mode-derived propagation velocity of the
descending thoracic aorta [aortic velocity propagation (AVP)] has been shown to
be associated with coronary and carotid atherosclerosis.
Patients
and Methods: The study population included 90 patients
with type 2 diabetes who had CKD (Group 1) and 40 age- and sex-matched patients
with type 2 diabetes who had a normal renal function (Group 2). Carotid
intima-media thickness (CIMT) and AVP were measured. Patients with known
coronary heart disease or end-stage renal disease were excluded.
Results:
Compared with Group 1, patients in Group 2 had
significantly lower AVP (Group 1= 29.85
± 3.95 cm/s and Group 2= 41.05 ± 3.34 cm/s, p< 0.001) and higher CIMT (Group
1= 1.06 ± 0.11 mm and Group 2= 0.78 ± 0.10 mm, p< 0.001). There were
significant correlations between AVP and CIMT (r= -0.669, p< 0.001).
Keywords
References
- 1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
- 2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-21.
- 3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al, European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1.
- 4. Niakan E, Harati Y, Rolak LA, Comstock JP, Rokey R. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986;146:2229.
- 5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154.
- 6. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
- 7. Gunes Y, Tuncer M, Guntekin U, Ceylan Y, Simsek H, Sahin M, et al. The relation between the color Mmode propagation velocity of the descending aorta and coronary and carotid atherosclerosis and flow-mediated dilatation. Echocardiography 2010;27:300-5.
- 8. Ognibene A, Grandi G, Lorubbio M, Rapi S, Salvadori B, Terreni A, et al. KDIGO2012 Clinical Practice Guideline CKD classification rules out creatinine clearance 24 hour urine collection? Clin Biochem 2016;49:85-9.
Details
Primary Language
English
Subjects
Clinical Sciences
Journal Section
Research Article
Authors
Türkan Mete
This is me
İsmail Özer
This is me
Yasemin Kaya
This is me
Ahmet Karataş
This is me
Publication Date
December 1, 2016
Submission Date
December 1, 2016
Acceptance Date
-
Published in Issue
Year 2016 Volume: 19 Number: 3